Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Author Archives: Warren Woessner
Eye Therapies v. Slayback Pharma – Fed. Cir. Enhances the Scope of “Consisting Essentially”
In Eye Therapeutics, LLC, v. Slayback Pharma, LLC., Appeal no. 2023-2173, (Fed. Cir., June 30, 2025), a panel of Judges Scarisi, Stoll and Tramto reversed a Board decision that the claims of U.S. Pat. No. 8,293,742 were invalid. Claim 1 … Continue reading
Posted in Claim Interpretation
Leave a comment
Sigray, Inc. v. Carl Zeis X-Ray Microscopy, Inc.—When does “No” Projection Magnification Mean “No”?
In Sigray, Inc, v. Carl Zeis X-Ray [“Zeiss”], appeal 2023-2211 (Fed. Cir., May 23, 2025), the panel reviewed the Board’s decision in an IPR in which Claims 1-6 of Zeiss patent no. 7,400,704 were held not to be unpatentable over … Continue reading
Posted in Claim Interpretation, Inherency, Uncategorized
Leave a comment
Regents of the U. of Cal. v. Broad Inst. – “Just The Facts, Ma’am.”
The central theme in this interference decision involving U.S. Pat. No. 8,697,359 is the amount and type of evidence required to support the conception of an invention. Joe Friday wanted the witness to focus on the facts of the matter, … Continue reading
Regeneron v. Mylan, “It Ain’t Necessarily So.”
Regeneron v. Mylan, appeal nos. 2024-2058, 2024-2147 (Fed. Cir., March 5, 2025) is the most recent appeal in a long line of Hatch-Waxman suits filed by Regeneron to block generic versions of its VEGF antagonist (or “trap”) EYLEA®, that is … Continue reading
Posted in Inherency
Leave a comment